Johnson & Johnson’s Depuy Synthes has acquired CrossRoads Extremity Systems from HealpointCapital for an undisclosed sum.

Omar Ford

February 14, 2022

1 Min Read
IMG_2022-2-14-132419.jpg
Image courtesy of GFC Collection / Alamy Stock Photo

Despite uncertainty with elective procedures, created by the pandemic, acquisitions are still happening in orthopedics. The latest deal involves Johnson & Johnson’s Depuy Synthes acquiring CrossRoads Extremity Systems from HealpointCapital for an undisclosed sum.

Through the acquisition Depuy Synthes would gain access to the Memphis, TN-based company’s broad portfolio of foot surgery with proven benefits such as dynaBunion4D, miniBunion3D, and DynaForce Staple Compression Plates. 

CrossRoads was founded in 2014. HealthpointCapital acquired a majority stake in the orthopedics company in 2019.

“Foot and Ankle surgery is a high growth sector in Orthopedics and the leading companies are searching for compelling, differentiated innovation,” said HealthpointCapital President Mike Mogul. 

HealthpointCapital said it had several other notable exits. The firm said the exits include OrthoSpace (acquired by Stryker), Blue Belt Technologies (acquired by Smith & Nephew), and BioHorizons (acquired by Henry Schein.)

News of the CrossRoads acquisition comes at a time when Johnson & Johnson is on the cusp of change – literally. The New Brunswick, NJ-based company said in November that it would split its consumer products business from its medical device and pharmaceutical businesses. The transaction is set to be complete within the next 18 to 24 months from November 2021.

 

 

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like